RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

CRISPR Therapeutics P/E 2024

CRISPR Therapeutics P/E

-8.97

CRISPR Therapeutics Dividend yield

Ticker

CRSP

ISIN

CH0334081137

WKN

A2AT0Z

As of May 17, 2024, CRISPR Therapeutics's P/E ratio was -8.97, a -73.04% change from the -33.27 P/E ratio recorded in the previous year.

The CRISPR Therapeutics P/E history

CRISPR Therapeutics Aktienanalyse

What does CRISPR Therapeutics do?

CRISPR Therapeutics AG is a company specializing in the development of therapies based on the gene editing technology CRISPR-Cas9. The company was founded in 2013 in Basel, Switzerland and is now headquartered in Zug, Switzerland. CRISPR Therapeutics is listed on the NASDAQ stock exchange and also has offices in the USA and London. CRISPR Therapeutics AG's history is closely linked to the discovery and development of the CRISPR-Cas9 technology. This revolutionary technique allows for the targeted modification, repair or elimination of certain genes in the genome of organisms. The technology was first discovered in the 1990s, but it was only in recent years with the development of CRISPR-Cas9 that it became possible to apply this technique in medical research. The goal of CRISPR Therapeutics AG is to use the CRISPR-Cas9 technology to develop therapies for life-threatening genetic diseases. The company works closely with the academic community and industry to develop innovative therapies and bring them through clinical trials. The business model of CRISPR Therapeutics AG is based on the development and commercialization of therapies based on the CRISPR-Cas9 technology. This involves using the technology to treat the genetic causes of serious diseases such as cystic fibrosis, sickle cell anemia, beta-thalassemia, or certain types of cancer. The company has a number of products in its pipeline and works closely with partners such as Vertex Pharmaceuticals and Bayer. CRISPR Therapeutics operates in the biotechnology industry and is divided into various divisions. For example, there is the research and development (R&D) division, which focuses on developing new therapies based on the CRISPR-Cas9 technology. Here, the company works on its own research projects as well as joint research projects with partners. There is also a clinical studies department that aims to test new therapies, prove their efficacy and safety in humans, and produce approved therapeutics. An example of a current product from the company is the CTX001 therapy, which involves stem cell transplantation using genetically modified stem cells from healthy donors to produce genetically error-free blood cells in the patient's body. CTX001 is currently in phase 1/2a clinical trials for the treatment of beta-thalassemia and sickle cell anemia, and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. In summary, CRISPR Therapeutics AG is a company in the biotechnology industry specializing in the development and commercialization of therapies based on the CRISPR-Cas9 technology. The company has a number of products in its pipeline and works closely with partners to develop innovative therapies and bring them through clinical trials. With the CRISPR-Cas9 technology, there is the potential to combat genetic diseases, which could have a significant impact on the treatment of diseases in the future. CRISPR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering CRISPR Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of CRISPR Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing CRISPR Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of CRISPR Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in CRISPR Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about CRISPR Therapeutics Stock

What is the price-to-earnings ratio of CRISPR Therapeutics?

The price-earnings ratio of CRISPR Therapeutics is currently -8.97.

How has the price-earnings ratio of CRISPR Therapeutics changed compared to last year?

The price-to-earnings ratio of CRISPR Therapeutics has increased by -73.04% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of CRISPR Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of CRISPR Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of CRISPR Therapeutics affect the company?

An increase in the price-earnings ratio of CRISPR Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of CRISPR Therapeutics affect the company?

A decrease in the price-earnings ratio of CRISPR Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of CRISPR Therapeutics?

Some factors that influence the price-earnings ratio of CRISPR Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does CRISPR Therapeutics pay?

Over the past 12 months, CRISPR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CRISPR Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CRISPR Therapeutics?

The current dividend yield of CRISPR Therapeutics is .

When does CRISPR Therapeutics pay dividends?

CRISPR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CRISPR Therapeutics?

CRISPR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CRISPR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CRISPR Therapeutics located?

CRISPR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CRISPR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CRISPR Therapeutics from 5/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/17/2024.

When did CRISPR Therapeutics pay the last dividend?

The last dividend was paid out on 5/17/2024.

What was the dividend of CRISPR Therapeutics in the year 2023?

In the year 2023, CRISPR Therapeutics distributed 0 USD as dividends.

In which currency does CRISPR Therapeutics pay out the dividend?

The dividends of CRISPR Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CRISPR Therapeutics

Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.